Immix Biopharma Inc

Immix Biopharma Inc(IMMX)のニュースとイベント

$7.980

-0.643 (-8.06%)終値時点

IMMX のニュース

IMMX のイベント

9/29 12:00

Major Averages Dip as 30-Year Bond Yield Hits Highest Level Since 2002

The major averages were fractionally lower near noon, adding to yesterday's declines as the 30-year bond yield hits the highest level since 2002. The losses may be somewhat mitigated by a dip in oil prices, though the commodity still remains above $90 per barrel amid continued tensions between the U.S. and Iran.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:OpenAI has scrapped the launch of its upcoming GPT-6.1 model amid security concerns, WSJ reportsMetaannounced Muse for Small BusinessOura said it is postponing its IPO due to "uncertainty" in the IPO marketCarMaxreported upbeat Q2 earnings and revenue and said it plans to resume share repurchases in Q3Carnivalreported better-than-expected Q3 results and provided upbeat FY26 guidance2. WALL STREET CALLS:Deutsche Bank upgraded Netflix, sees attractive entry point after selloffPepsiCowas downgraded for a second straight day, with JPMorgan citing a stalled U.S. turnaroundMizuho upgraded Stitch Fixto Neutral with short case played outMonday.comdowngraded to Neutral at JPMorganGoosehead Insuranceupgraded to Buy at Texas Capital after Muse-driven selloff3. AROUND THE WEB:Piper Sandlerhas been in talks to acquire Perella Weinberg Partners, WSJ reportsJoost van Dreunen, an industry expert, told Bloomberg that Robloxwill benefit from the Take Two'sNovember's release of "Grand Theft Auto VI"Googlehas challenged two orders from the EU to help AI rivals access its services and search engine competitors use its search engine data, Reuters reportsAI research leaders at OpenAI, Anthropic, Microsoft, and Metaare calling for oversight into automated AI research, WSJ reportsAnthropic plans to spend $518B on cloud/infrastructure obligations, Reuters says4. MOVERS:Iovance Biotherapeuticsgains after raising its outlook for FY26Sweetgreenincreases after naming Baz as its first Chef in ResidenceOraclehigher after announcing a new storage service for cloud with NetAppuniQurefalls in New York after announcing additional data from its studies of ifezuntirgene inilparvovecImmix Biopharmalower after pricing its 11.36M share offering5. EARNINGS/GUIDANCE:AAR Corp.reported Q1 results and provided guidance for Q2 and FY27IDT Corp.reported Q4 results, with EPS higher year-over-yearBWX Technologiesprovided guidance for FY26 and FY30SmartStop Self Storageraised its outlook for FY26Jefferies Financialreported Q3 results, with EPS and revenue beating consensusINDEXES:Near midday, the Dow was down 293.73, or 0.57%, to 51,187.78, the Nasdaq was down 21.83, or 0.08%, to 26,798.55, and the S&P 500 was down 19.07, or 0.25%, to 7,664.62.

9/29 07:30

Immix Biopharma NXC-201 Achieves 89% Complete Response Rate

Immix Biopharma announced positive results of an 89% complete response, CR, rate in an interim update across all forty-five NEXICART-2 patients, advancing NXC-201 as a potential best-in-class therapy for AL Amyloidosis. All twenty-five new relapsed/refractory AL Amyloidosis patients are either in complete response or already minimum residual disease-negative. To-date, all patients achieving MRD-negativity reached CR within one year of treatment. Across all forty-five patients, NXC-201 produced an 89% CR rate as assessed by independent review committee. In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to 98%. No relapses to date have been observed for any patient who reached CR or MRD-negativity to-date. No neurotoxicity or enterocolitis has been observed to-date. NEXICART-2 final readout and BLA submission are planned in 2027.

9/29 07:30

Immix Biopharma Prices 11.36M Shares at $11 Each

Immix Biopharma announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125M, before deducting underwriting discounts and commissions and offering expenses payable by the company. The offering is expected to close on or about September 30, subject to the satisfaction of customary closing conditions. J.P. Morgan is acting as the sole book-running manager for the offering.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める